Compare PERI & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PERI | DSGN |
|---|---|---|
| Founded | 1999 | 2017 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 412.5M | 418.1M |
| IPO Year | 2006 | 2021 |
| Metric | PERI | DSGN |
|---|---|---|
| Price | $10.26 | $9.22 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $14.75 | $13.00 |
| AVG Volume (30 Days) | 401.7K | ★ 457.9K |
| Earning Date | 11-12-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $432,361,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $11.12 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.00 | $2.60 |
| 52 Week High | $11.79 | $9.85 |
| Indicator | PERI | DSGN |
|---|---|---|
| Relative Strength Index (RSI) | 60.74 | 71.64 |
| Support Level | $9.30 | $8.21 |
| Resistance Level | $9.96 | $9.85 |
| Average True Range (ATR) | 0.41 | 0.68 |
| MACD | 0.05 | 0.20 |
| Stochastic Oscillator | 54.50 | 82.97 |
Perion Network Ltd is a technology company. It offers online advertising and search solutions to brands, agencies, and publishers through desktop, mobile, and social channels. It connects advertisers to consumers across digital advertising channels, including search advertising, social, display, video, digital audio, digital out of home (DOOH), and Connected TV (CTV) advertising. The company earns prime revenue from search advertising and display advertising services. It operates in the business segment of High Impact Advertising solutions. Geographically, the company generates a majority of its revenue from the United States and the rest from other regions.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.